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Abstract 
Purpose: To identify protein targets in host (vero) cell since there is currently no therapy or a licensed 
tetravalent vaccine to combat all the four virus serotypes of dengue virus.  
Methods: The domain III of the dengue virus encoded envelope protein was expressed in pET28a 
expression vector and the purified recombinant protein was labeled with biotin without altering its 
immunogenicity. Vero cell proteins on nitrocellulose membrane reacted with recombinant envelope 
protein domain III to identify viral target proteins in vero cells.  
Results: The 45 KDa, 43 KDa and 30 KDa plasma membrane proteins were identified as viral envelope 
targets. Competitive binding assay showed these proteins competing with dengue virus binding. MTT 
assay indicate that viability of vero cells increases in cultures pretreated with 45 KDa, 43 KDa and 30 
KDa proteins before dengue infection.  
Conclusion: These results indicate the possible role of these proteins in viral binding to vero cells. The 
study provides a preliminary insight that would aid in determining the target epitopes against protein E 
domain III of dengue virus and hence, formulation of a vaccine for preparing neutralizing antibodies. 
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Dengue virus belongs to the family Flaviviridae 
and includes immunologically four different 
serotypes (DEN-1, 2, 3 and DEN-4) [1]. The virus 
is transmitted through Aedes mosquito [2] and 
causes infections that range from dengue fever 
(DF) to life-threatening dengue hemorrhagic 
fever (DHF) and dengue shock syndrome (DSS). 
Despite current efforts to control dengue, based 
primarily on vector control and case 
management, the burden of the disease remains 
considerable. Dengue virus is a single-stranded, 
positive sense RNA virus with an 11kb non-
fragmented genome surrounded by a lipid bilayer 
envelope. RNA codes for three structural 
proteins and seven non-structural proteins. The 
three structural proteins are C (nucleocapsid), M 
(membrane associated protein) and E (envelope 
protein) and the seven non-structural proteins 
are designated as NS1, NS2, NS3, NS4, NS5, 
NS6 and NS7.  
 
To establish infection virus requires entry into 
cells, followed by release of nucleocapsid. This is 
achieved by the fusion of the viral membrane 
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with a cellular membrane [3,4]. The initial binding 
of dengue virus to target cells is mediated by 
binding of the envelope protein to a specific and 
unidentified cell surface receptor(s) [5].  
 
Viral interaction with its targets observed by 
electron microscopy has been already reported 
[6]. The structure of the ectodomain of DEN-2E 
protein [7] shows it to be similar to that of the E 
protein of the Tick–Borne Encephalitis virus 
(another member of the Flaviviridae family) [8]. 
The E protein is organized into distinct domains 
designated as I, II and III. Of these, domain III 
(300 – 400aa), which has a single disulfide bond, 
is of particular importance from the viewpoint of 
vaccine development as it contains multiple 
serotype specific conformation-dependent, 
neutralizing epitopes and the host cell receptor 
recognition site [9]. The aim of present study was 
to identify the potential target proteins in the host 
cell that are involved in binding to E-protein to 




Preparation of dengue type 2 virus RNA and 
E gene domain III coding sequence 
 
Vero cells were grown at 37 oC in a humidified 
incubator using 5 % CO2, RPMI 1640 medium 
(Gibico, Grand Island, NY) supplemented with 10 
% fetal bovine serum (FBS), penicillin and 
streptomycin. Cells were infected (MOI = 0.1 – 
0.2 PFU/cell) with dengue type 2 virus (isolated 
clinically).  Four days after infection, total RNA 
was extracted using QIAmp viral RNA mini kit 
(Qiagen, Chatsworth, CA), according to 
manufacturer’s instructions. Viral genomic RNA 
was used as a template to obtain the DEN-2 
virus E gene fragment (aa 295 – 400) DNA by 
one-step RT-PCR (Qiagen), with parameters as 
follows: 50 °C for 30 min, 95 °C for 15 min, and 
40 cycles of 94 °C for 15 s, 55 °C for 30 s, 72 °C 
for 1 min, with a final extension at 72 °C for 2 




(the italicised sequence is BamHIrestriction site),  
 




3’ (italic sequence is XhoI restriction site).  
 
After PCR, a 318 bp of the DEN-2 E gene 
domain III sequence was obtained, with flanking 
BamHI and XhoI restriction sites.  
 
Construction of recombinant expression 
plasmid and purification of recombinant E-
protein  
 
The PCR product was purified with a Qiaquick 
DNA purification kit (Qiagen) and digested with 
BamHI and XhoI, then ligated into the 
corresponding BamHI and XhoI restriction sites 
in the expression vector pET28a (Novagen, 
Darmstadt, Germany), generating a recombinant 
plasmid, pET28a-DEN2EDIII. The construct was 
identified by T7 sequencing primer and 
compared with data reported for NGC strain 
sequence (Genbank accession no. D00346). The 
culture was grown and lysed as previously 
described [9]. The lysate was purified by Ni-NTA 
affinity matrix (Qiagen) and the flow-through was 
collected. The column was washed with 50 ml 
wash buffer (20 mM phosphate buffer pH 7.5/300 
mM NaCl/20 mM imidazole) and eluted 
sequentially with 100, 250, and 500 mM 
imidazole containing buffers. The emergence of 
proteins was monitored by Bradford method. The 
protein-containing fractions were analyzed by 
SDS-PAGE as described by Laemmeli in 1970 
[10]. The relevant fractions were pooled and 
dialyzed against PBS. 
 
Biotinylation of purified recombinant E 
protein 
 
Sequence analysis of recombinant dengue type 
2 envelope domains III shows 17 lysine (K) 
residues and hence was labelled with biotin. EZ-
Link® Sulfo-NHS-Biotinylation kit was procured 
from Pierce and rDEN2EDIII was biotinylated 
according to supplier’s protocol with minor 
modifications. Excess of biotin reagent was 
removed by desalting columns and HABA (4’-
hydroxyazobenzene-2carboxylic acid) assay was 
done for measuring the level of biotin 
incorporation. Label incorporation was estimated 
by adding the biotinylated protein to mixture of 
HABA dye and avidin and ODs were compared 
and values calculated using HABA calculator on 
http://www.piercenet/haba.com.  
 
Western blotting  
 
Total protein was extracted from infected vero 
cells by RIPA buffer and transferred to 
nitrocellulose membrane which was later blocked 
with 5 X skimmed milk for 2 h at room 
temperature. Diluted biotin antibody (BTN4 from 
Thermo Scientific, Pierce) (final concentration 0.1 
- 5 μg/ml) was added and incubated overnight on 
shaker in 4 oC. Next day membrane was washed 
5 - 6 times with PBST and incubated with 
streptavidin HRP solution (1:5,000 dilution) 
(Pierce) for 2 h at room temperature. The 
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membrane was again washed 5-6 times with 
PBS-T and hybridized with substrate reagent (2 
mg DAB in PBST + 20 μL of 30 % H2O2). Color 
development was achieved by gentle shaking for 
5 min at RT and bands showing hybridization 
signals were detected.  
 
Treatment of vero cells with electroeluted 
proteins before dengue-2 challenge 
 
Vero cell line was cultured in RPMI1640 medium 
containing 10 % fetal bovine serum. The culture 
was set in 25 cm2 tissue culture flasks and 
incubated to achieve a level of 80 % 
confluences. Cultures were washed once with 
PBS before infection. For infection, the cells were 
passaged in 6, 24 or 96 well plates to a 
confluence of 80 %. Each group of cells were 
infected with 5, 10 and 20 µg of purified 
recombinant E- protein for 30 min at room 
temperature and kept for rocking at room 
temperature for 1 h to check the proper 
concentration of recombinant protein to be used.   
 
Methylthiazol tetrazolium assay on cells 
 
Recombinant electro eluted  protein was further 
purified with dialysis in 0.2 X RIPA buffer and 
serial dilution of purified protein was mixed with 
dengue virus type 2, NGC strain. The mixture 
was added to Vero cells to assess the ability to 
protect cells from DEN-2 virus infection. MTT 
assay was done to check the viability of cells 
before and after treatments as previously 
described [11] to determine the ability of the 
purified electro eluted proteins to block DEN-2 
binding to Vero cells.In this process, the cells 
were passaged at 5 × 105 cells per well in 6-well 
plates and incubated at 33 °C with 5 % CO2 for 
36 – 48 h. Serial dilution of the purified 
rDEN2EDIII or BSA (as negative control) in RPMI 
medium was added to 0.5 ml of DEN-2 strain in 
amount of 80 – 100 pfu/well. Protein 
concentration in each case ranged from 0 to 10 
µg/well. The mixtures were added onto Vero 
cells in 6 - well plates and incubated at 33 oC 
with 5 % CO2 for 1 h. After aspiration of the 
protein/virus mixtures, RPMI medium (containing 
0.8 % agarose) was added to the well and 
incubated at 37 °C with 5 % CO2 for 3 days. 200 
µL MTT (Methylthiazol Tetrazolium Assay) (5 
mg/mL in PBS) was added to the wells to stain 




Comparison between different groups was done 
using Independent samples t-test. P ≤ 0.05 was 
considered statistically significant. All statistical 
calculations were done using Statistical Package 





Cloning and expression of rDEN2EIII 
 
The domain III of dengue virus type 2 E-protein 
(318 bp) was obtained by reverse transcription 
PCR (Figure 1a). The amplified fragment was set 
up for digestion with BamH1 and Xho1. Vector 
pET 28a was also digested with the same 
enzymes and purified by gel extraction. The 
ligation was done to obtain the construct, 
pET28a-DEN2EIII. Colony PCR was done 
(Figure 1b) and the clone that gave a band at 
318 bp was chosen for plasmid extraction. The 
recombinant plasmid was sequenced with T7 
sequencing primer. Sequencing verified the 
insert that assembled to reference sequence 
from the NGC strain with 100 % homology.  
 
The recombinant plasmid supported the high 
level synthesis of domain III of E-protein and was 
further purified by Ni-NTA affinity 
chromatography under denaturing conditions. 
The purified protein gave a band at 16KDa on 
SDS-PAGE (Figure 2). Approximately 80 – 90 % 
of the induced protein bound to the column, as 
evident from the comparison of a polypeptide 
profile of the lysate loaded on affinity matrix 
column with that of flow through material (Lane 
2). Based on a comparison of the host band 
intensities in these two lanes, it appears that no 
or very little non-specific binding to the affinity 
matrix occurred. Elution with a buffer (pH 4.5) 
resulted in the emergence of highly purified 
recombinant protein from the column (lane1). 
Hence > 90 % purity has been achieved for 
rD2EIII protein after expression in pET28a and 
purification on Ni-NTA affinity matrix. The yield of 
purified rD2EIII protein was 25 – 30 mg/L from 
induced culture. 
 
Biotinylation of purified recombinant protein 
rDEN2EIII 
 
Spectrophotometric reading of HABA-avidin (H/a) 
and that of HABA-avidin-biotinylated protein 
(Ha/b) showed incorporation of 1.61 moles of 
biotin/mole of protein. These calculations were 
made on the basis of HABA calculator available 
on pierce website. 
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Figure 1:  (a) PCR fragment of a 318 bp of the DEN-2 E gene domain III sequence with flanking BamHI and XhoI 
restriction sites. Lane 1 is HaeIII digest of ΦX174 from NEB and lane 2 is 318 bp fragments; (b) Colony PCR from 




Figure 2: SDS-PAGE showing the purified DEN2E 
domain after Ni-NTA purification. Lane 1 (DEN2E), 
Lane 2 (flow through) showing high affinity of DEN2E 
to column and Lane 3 (marker) 
 
Identifying proteins that react to rDEN2EIII 
 
The total cellular protein from Vero cell was 
extracted with quantitative yield of nearly 1.3 
µg/106 cells. When these gels were transferred to 
nitrocellulose membrane and hybridized with 
biotinylated envelope protein, signals at 45 KDa, 
43 KDa and 30 kDa were obtained. No spot was 
seen in control gel (without rD2EIII) which means 
that signals were not due to internal biotin 
residues hence confirming that the interactions 
were specific. 
  
Evaluation of electro eluted vero cell proteins 
in vero cells by competitive blocking assay 
 
It was expected that the purified protein(s) have 
role in viral binding and hence they should alter 
dengue virus binding to these cells. When the 
cell cultures were pre-immune-stimulated with 
electro eluted proteins prior to dengue viral 
infections, the growth of cultures was more in 
comparison to the cultures that were not pre 
immunized or stimulated. It was found that the 
plaque forming units were less in pre-stimulated 
cell cultures of cells. There was significant (p > 
0.0001) difference between the groups pre-
stimulated with 45 and 43 KDa protein and 
normal group respectively, while the difference 
was non-significant (p = 0.873) between the 
group stimulated with 30 KDa  and normal group 
(Table 1). 
 
MTT assay  
 
Cell viability checked with MTT assay showed 
that all the three proteins increased the cell 
viability and decreased dengue virus interaction. 
The cells without pre-treatment with the above 
mentioned proteins had decreased cell viability 
and increased apoptosis (Figure 3). All the three 
purified proteins were added to vero cells before 
infection with equal quantity of 25 µM. It was 
found that 45 KDa protein increased cell viability 
by 50-fold approximately, 30 KDa protein 
increased cell viability by 45 % and 43 KDa 
protein increased cell viability by approximately 
25 %. 
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Table 1: Averaged data from three replicate plaque assays of DENV2 titres in cell culture supernatants (each 
duplicate) after stimulation with eluted proteins 
 
Group PFU/mL at M.O.I ≤10 
± SEM 
P-value 
Vero+RPMI+DEN 6.23x104 ± 1.41 
2.13x103 ± 0.82 
4.10x103 ± 0.73 
5.67x104 ± 3.60 
 
Vero+45KDa+DEN   >0.0001* 
Vero+43KDa+DEN  >0.0001* 
Vero+30KDA+DEN 0.873 
PFU = Plaque forming units. P values are for student’s t of comparisons with PBS treated cells; SEM is standard 




The infective domain of dengue virus envelope is 
responsible for virus attachment and entry to 
host cells and is considered as a promising 
subunit for its neutralizing epitopes and host cells 
receptor recognition site. It has been reported 
that the E protein maybe an effective subunit 
vaccine candidate because of its capacity to bind 
with host cell surface receptors. Also it has the 
ability to elicit protective antibodies against virus 
infection [12]. Recombinant E protein has been 
expressed in different expression systems like E. 
coli and P. pastoris [13,14].  
 
In the present study E protein was expressed in 
E. coli and labeled with biotin after purification. 
The recombinant fusion protein could inhibit 
plaque formations in the host cell caused by 
dengue viral infections up to greater than 80 %. 
Recombinant domain III protein fused with His 
tag was checked for immunogenicity and it was 
again more than 90 % active immunologically. An 
earlier study showed that the recombinant 
domain III protein fused with Protein A was not 
immunogenic. The high binding affinity of Protein 
A to human immunoglobulins makes it 
impossible to use such proteins as a vaccine 
candidate [15]. In this study, a domain III 
fragment (295 – 400 aa) of DEN-2 E protein 
expressed in E. coli with a His tag carrier protein 
was produced because his tag is very small and 
doesn’t interfere with E-protein’s immunologic 
activity. His tag offers the advantage that it is 
poorly immunogenic and need not be removed 




Figure 3: Effect of electro eluted proteins on cell viability. Cells were pretreated with 25 µM of each purified 
protein. 1. Pre-treatment with 45 KDa proteins 2. Pre-treatment with 43 KDa protein and 3. Pre-treatment with 30 
KDa proteins. Data shown are triplicates of three consecutive experiments 
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The use of the 6XHis tag obviates the need of 
subjecting the recombinant domain III protein to 
protease treatment and the inherent risk of 
recombinant protein degradation [16]. To identify 
the human cellular proteins interacting with the 
envelope protein of dengue virus serotype 2 
inside host cells protein-protein interaction has 
been focused in present study. Protein-protein 
interaction studies are recent ideas for studying 
interaction of viral particles with host cells [17-
20]. 
 
In order to determine whether the purified 
recombinant protein retains the ability to bind 
with host cells or not, a competitive blocking 
assay was carried out. The result showed that 
the purified recombinant protein protects host 
cells from DEN-2 virus infection. It is likely that 
the recombinant protein was correctly refolded 
without loss of its biological function.  
 
After verification of biological function, the 
recombinant E protein was labeled by biotin. 
Biotin has a small size and hence does not alter 
the structure and functions of purified protein 
when used as a probe.  We found the three 
signals at molecular weights 45 KDa, 43 KDa 
and 30 KDa. Also, there was no signal on 
nitrocellulose when only biotin without the 
dengue virus envelope was hybridized. This 
showed that the interaction was not because of 
internal biotin or biotinylated proteins in the cell 
but entirely specific to recombinant E-protein. 
Electro eluted 45 KDa, 43 KDa and 30 KDa 
proteins added to vero cells prior to virus 
infection inhibited virus binding and increased 
cell viability. This feature may be attributed to 
decreased apoptosis in the cells due to pre 
stimulation by eluted proteins. It was previously 
described by us that infection with dengue virus 
increases apoptosis and decreases cell viability 
[6].  
 
The ability of many viruses to manipulate the 
host antiviral immune response often results in 
complex host-pathogen interactions. DENV-
infected cells are less able to produce 





The recombinant envelope protein produced is 
capable of inducing neutralizing antibodies which 
is consistent with previous studies. Furthermore, 
45 KDa, 43 KDa and 30 KDa proteins in vero 
cells that interact with dengue virus envelope 
protein have been identified. All these proteins 
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